Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.25 USD | -3.63% | -3.35% | -34.43% |
05-31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
05-24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.43% | 4.76B | |
-1.85% | 89.87B | |
-3.95% | 37.57B | |
+61.72% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+4.42% | 9.11B | |
-19.53% | 7.32B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Shares Rise on Updates for US Prescribing Information for Syfovre